Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience.

Christopher Francis JanowakBradley Robert BeckerCarolyn Dosen PhilpottAmy Teres MakleyEric William MuellerChristopher Allen Droege Molly Elizabeth Droege

Published in: The Annals of pharmacotherapy (2022)

Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.

Keyphrases

replacement therapy
spinal cord injury
cross sectional
solid phase extraction
combination therapy
case control
smoking cessation